Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31256689 | 0.84 | KDM4E (0.41) | MAPK1ALDH1A1KDM4ETDP1 | |
| SCHEMBL29284672 | 0.84 | PTGS2 (0.30) | PTGS2MAPK1 | |
| SCHEMBL31256685 | 0.83 | TYK2 (0.37) | MAPK1TDP1 | |
| SCHEMBL13732956 | 0.77 | SPR (0.32) | PTGS2MAPK1ALDH1A1 | |
| SCHEMBL12447413 | 0.72 | MAPK1 (0.37) | PTGS2MAPK1ALDH1A1KDM4ETDP1 | |
| SCHEMBL3050197 | 0.72 | RAB9A (0.49) | PTGS2MAPK1ALDH1A1KDM4ETDP1 | |
| SCHEMBL6156185 | 0.71 | LMNA (0.37) | PTGS2MAPK1KMOALDH1A1 | |
| SCHEMBL30880982 | 0.70 | NAMPT (0.43) | — | |
| SCHEMBL16973433 | 0.70 | KMT2A (0.40) | — | |
| SCHEMBL574416 | 0.69 | KDM4E (0.49) | MAPK1ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435065-B2 | Crystalline forms of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide | BASF SE (DE) | 2025-10-07 | — | — | US | disclosed |
| WO-2025082385-A1 | PYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东省联合农药工业有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119330882-A | Pyrazole amide compound and application thereof | 河北蓝泰化工科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119101038-A | Pyridazine compound and preparation method and application thereof | 山东省联合农药工业有限公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-3908584-B1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20220024898-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2022-01-27 | — | — | US | disclosed |
| EP-3908584-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2021-11-17 | — | — | EP | disclosed |
| CN-113272296-A | Crystalline forms of 1- (1, 2-dimethylpropyl) -N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide | 巴斯夫欧洲公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020144308-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024898-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | CRY1, PRMT5, KDM5D | PTGS2 2781/4885MAPK1 842/4885KMO 1085/4885 |
| US-12435065-B2 | Crystalline forms of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide | CRY1, PRMT5, KDM5D | PTGS2 2781/4885MAPK1 842/4885KMO 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.